1. Home
  2. TAL vs BLCO Comparison

TAL vs BLCO Comparison

Compare TAL & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TAL Education Group

TAL

TAL Education Group

HOLD

Current Price

$11.11

Market Cap

6.6B

Sector

Real Estate

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.94

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAL
BLCO
Founded
2003
1853
Country
China
Canada
Employees
N/A
N/A
Industry
Other Consumer Services
Ophthalmic Goods
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
6.0B
IPO Year
2010
2022

Fundamental Metrics

Financial Performance
Metric
TAL
BLCO
Price
$11.11
$16.94
Analyst Decision
Buy
Hold
Analyst Count
4
14
Target Price
$12.66
$17.31
AVG Volume (30 Days)
2.7M
338.6K
Earning Date
01-29-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
136.94
N/A
EPS
0.28
N/A
Revenue
$2,653,037,000.00
$4,976,000,000.00
Revenue This Year
$35.72
$8.06
Revenue Next Year
$24.33
$5.79
P/E Ratio
$39.81
N/A
Revenue Growth
44.45
6.23
52 Week Low
$8.50
$10.45
52 Week High
$15.30
$18.14

Technical Indicators

Market Signals
Indicator
TAL
BLCO
Relative Strength Index (RSI) 47.96 49.10
Support Level $10.64 $16.85
Resistance Level $11.40 $17.54
Average True Range (ATR) 0.42 0.43
MACD -0.05 -0.06
Stochastic Oscillator 25.56 47.56

Price Performance

Historical Comparison
TAL
BLCO

About TAL TAL Education Group

TAL Education Group is a smart learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: